Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia.
bendamustine
chronic lymphocytic leukemia
efficacy
elderly
lymphoma
safety
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Mar 2021
30 Mar 2021
Historique:
received:
19
02
2021
revised:
19
03
2021
accepted:
25
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated. An observational, retrospective study was carried out; patients with chronic lymphocytic leukemia (CLL) or lymphoma, aged ≥ 65 years old, treated with bendamustine-based regimens in first or subsequent lines between 2010 and 2020 were considered eligible. Overall, 179 patients aged ≥ 65 years were enrolled, 53% between 71 and 79 years old. Cumulative Illness Rating Scale (CIRS) comorbidity score was ≥6 in 54% patients. Overall survival (OS) at 12 months was 95% (95% confidence interval [CI]: 90-97%); after a median follow up of 50 months, median OS was 84 months. The overall response rate was 87%, with 56% complete responses; the median time to progression (TTP) was 61 months. The baseline factors affecting OS by multivariable analysis were sex, histological diagnosis, renal function, and planned bendamustine dose, while only type of lymphoma and bendamustine dose impacted on TTP. Main adverse events were neutropenia (grade ≥ 3: 43%) and infections (any grade: 36%), with 17% of patients requiring hospital admission. The responses to bendamustine, as well as survival, are relevant even in advanced age patients, with a manageable incidence of acute toxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated.
METHODS
METHODS
An observational, retrospective study was carried out; patients with chronic lymphocytic leukemia (CLL) or lymphoma, aged ≥ 65 years old, treated with bendamustine-based regimens in first or subsequent lines between 2010 and 2020 were considered eligible.
RESULTS
RESULTS
Overall, 179 patients aged ≥ 65 years were enrolled, 53% between 71 and 79 years old. Cumulative Illness Rating Scale (CIRS) comorbidity score was ≥6 in 54% patients. Overall survival (OS) at 12 months was 95% (95% confidence interval [CI]: 90-97%); after a median follow up of 50 months, median OS was 84 months. The overall response rate was 87%, with 56% complete responses; the median time to progression (TTP) was 61 months. The baseline factors affecting OS by multivariable analysis were sex, histological diagnosis, renal function, and planned bendamustine dose, while only type of lymphoma and bendamustine dose impacted on TTP. Main adverse events were neutropenia (grade ≥ 3: 43%) and infections (any grade: 36%), with 17% of patients requiring hospital admission.
CONCLUSIONS
CONCLUSIONS
The responses to bendamustine, as well as survival, are relevant even in advanced age patients, with a manageable incidence of acute toxicity.
Identifiants
pubmed: 33808164
pii: jpm11040249
doi: 10.3390/jpm11040249
pmc: PMC8066290
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Lancet Oncol. 2016 Jan;17(1):57-66
pubmed: 26655425
Clin Infect Dis. 2019 Jan 7;68(2):247-255
pubmed: 29800121
J Clin Oncol. 2019 Apr 20;37(12):984-991
pubmed: 30811293
Haematologica. 2018 Apr;103(4):698-706
pubmed: 29419437
Nephron. 1976;16(1):31-41
pubmed: 1244564
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Hemasphere. 2020 Dec 29;5(1):e520
pubmed: 33403356
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
Hematol Oncol. 2020 Oct;38(4):509-516
pubmed: 32400885
Hematol Oncol. 2017 Dec;35(4):424-431
pubmed: 27734524
Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54
pubmed: 25829094
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Leuk Lymphoma. 2016;57(4):766-82
pubmed: 26592922
Anticancer Res. 2016 Jun;36(6):2827-38
pubmed: 27272794
Br J Haematol. 2017 Sep;178(5):820-823
pubmed: 27377970
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Expert Rev Hematol. 2017 Aug;10(8):707-718
pubmed: 28664772
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood Cancer J. 2015 Oct 23;5:e362
pubmed: 26495859
Haematologica. 2018 Jul;103(7):1209-1217
pubmed: 29674504
J Cancer Res Clin Oncol. 2001 Jan;127(1):48-54
pubmed: 11206271
Br J Haematol. 2021 Apr;193(2):280-289
pubmed: 33476434
J Clin Oncol. 2020 Dec 1;38(34):4042-4054
pubmed: 32986498
Lancet Oncol. 2017 Mar;18(3):297-311
pubmed: 28139405
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Clin Oncol. 2020 Sep 1;38(25):2849-2861
pubmed: 32459600
J Clin Oncol. 2018 Aug 10;36(23):2395-2404
pubmed: 29856692
Cancer Med. 2020 Nov;9(22):8468-8479
pubmed: 32969597
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009045
pubmed: 22972131
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Br J Haematol. 2020 Nov;191(3):426-432
pubmed: 32779190
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739